Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TOP2A | P11388 | 3/20 | 0.41 |
| ▸ | CNR2 | P34972 | 3/20 | 0.38 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | VDR | P11473 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6276710 | 1.00 | CYP1A2 (0.42) | CYP1A2KDM4EMEN1CYP2C19KMT2A | |
| SCHEMBL6276266 | 1.00 | CYP1A2 (0.42) | CYP1A2KDM4EMEN1CYP2C19KMT2A | |
| SCHEMBL6274542 | 0.96 | CYP1A2 (0.43) | CYP1A2KDM4EMEN1CYP2C19KMT2A | |
| SCHEMBL6274316 | 0.91 | CNR2 (0.40) | TOP2ACNR2 | |
| SCHEMBL6270707 | 0.91 | CNR2 (0.40) | TOP2ACNR2 | |
| SCHEMBL6276756 | 0.88 | CYP1A2 (0.46) | CYP1A2KDM4EMEN1CYP2C19KMT2A | |
| SCHEMBL8497264 | 0.88 | CNR2 (0.46) | KDM4EMEN1KMT2ACNR2LMNA | |
| SCHEMBL6276200 | 0.86 | CNR2 (0.43) | KDM4EMEN1KMT2ACNR2LMNA | |
| SCHEMBL6276043 | 0.86 | CNR2 (0.43) | KDM4EMEN1KMT2ACNR2LMNA | |
| SCHEMBL6277139 | 0.86 | CNR2 (0.43) | KDM4EMEN1KMT2ACNR2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1273578-B1 | Benzopyran derivatives and antiallergic agent containing the same | DAINIPPON INK & CHEMICALS (JP) | 2005-02-23 | — | — | EP | disclosed |
| US-6670391-B2 | For inhibiting both immediate and delayed type allergic reactions; side effect reduction | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2003-12-30 | — | — | US | disclosed |
| US-20030096860-A1 | Benzopyran derivative and antiallergic agent | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2003-05-22 | — | — | US | disclosed |
| EP-1273578-A1 | Benzopyran derivatives and antiallergic agent containing the same | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2003-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096860-A1 | Benzopyran derivative and antiallergic agent | HRH2, HRH1, HRH4 | CYP1A2 41/4885KDM4E 965/4885MEN1 4691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.